Skip to main content
. Author manuscript; available in PMC: 2022 Dec 1.
Published in final edited form as: Neuropharmacology. 2021 Oct 2;200:108819. doi: 10.1016/j.neuropharm.2021.108819

Figure 6. Intra-BLA antalarmin or CRF pre-treatment does not alter locomotor activity in a novel context three days later.

Figure 6.

Rats received intra-BLA administration of antalarmin (Anta; 500 ng/0.5 μL per hemisphere), corticotropin-releasing factor (CRF; 0.2, 30, or 500 ng/0.5 μL per hemisphere), or their respective vehicles (VEH) three days prior to a 2-h locomotor activity test in a novel chamber. (A) Total number of photobeam breaks (mean/2 h ± SEM) elicited by males and females that received intra-BLA VEH (n = 6 males, 5 females) or Anta pre-treatment (n = 6 males, 6 females). (B) Total number of photobeam breaks (mean/2 h ± SEM) elicited by males that received intra-BLA vehicle or CRF (500 ng/hemisphere) pre-treatment (n = 4/group). (C) Total number of photobeam breaks (mean/2 h ± SEM) elicited by females that received intra-BLA vehicle or CRF (0.2, 30, or 500 ng/hemisphere) pre-treatment (n = 5–8/group). Symbols: Silcrow indicates difference from males during the first time bin, §ANOVA sex simple-main effect collapsed across treatment, Tukey’s test. Asterisk indicates difference from vehicle treatment at a time bin, *ANOVA treatment simple-main effect collapsed across sex. Double daggers indicate difference from subsequent time bins, ‡ANOVA time simple-main effect collapsed across treatment, but not sex (Panel A) or time main effect collapse across treatment (Panels B, C).